Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

ANNAPOLIS, Md., April 28 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conference on Vaccine Research, being held in Baltimore, MD, April 27-29, 2009. The conference is sponsored by the National Foundation of Infectious Diseases.

David P. Wright, President and Chief Executive Officer of PharmAthene commented, "We are very pleased to have had the opportunity to present these latest data for SparVax(TM) at Annual Conference on Vaccine Research. The study, which compared our vaccine to the currently licensed anthrax vaccine, BioThrax(R), provides further confirmation that SparVax(TM) is immunogenic and promotes good immunological recall following antigenic challenge. In addition, a lower incidence of injection site reactions observed with SparVax(TM) may suggest that it is better tolerated than BioThrax(R), a very important finding for this product candidate. Presentation of these data to attendees at this conference allows PharmAthene to continue to increase awareness of the progress we are making developing improved products using modern vaccine technologies to protect our Nation's citizens and military."

SparVax(TM) is a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection.

SparVax(TM) Phase II Clinical Data

Results from a Phase II clinical trial of SparVax(TM) were presented during a poster session by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene.

The study was one of two Phase II trials evaluating different dose and dosing regimens of Sp
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... and TORONTO , Sept. ... www.generex.com ) (OTCBB:GNBT) today announced that it has ... (UHN) pursuant to which UHN,s Centre for Molecular ... buccal insulin refinement project.  The goal of the ... Generex Oral-lyn™, the Company,s proprietary buccal insulin spray ...
(Date:9/22/2014)... FierceBiotech today announced its annual “Fierce 15” ... 2014. FierceBiotech editors John Carroll and Damian Garde ... Those selected are identified as some of the ... , "It's always a lot of fun to ... said Carroll. "This year in particular you'll find quite ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
(Date:9/22/2014)... Synageva BioPharma Corp. ("Synageva") ... developing therapeutic products for rare disorders announced today ... Chief Operating Officer.  Reporting directly to Sanj ... Robert will oversee the planned global commercial launch ... LAL Deficiency, and will have responsibility for the ...
Breaking Biology Technology:Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4
... (NYSE: SPW ) today announced that it ... leading engineering company supplying processing solutions for the food ... New Zealand. Terms of the acquisition were not disclosed. ... in the New Zealand dairy, beverage and bio-tech markets, ...
... advisory committee recommended today that the Food and Drug ... US as a once-daily long-term maintenance bronchodilator treatment of ... (COPD), including chronic bronchitis and/or emphysema. ... recommending approval of the 75 mcg dose. The advisory ...
... In addition to reliable high efficiency transfection reagents, ... development of the Reagent Agent(SM) - a new online ... of any nucleic acid into any cell type, including ... based on extensive in-house transfection and electroporation data, customer ...
Cached Biology Technology:SPX Announces Acquisition of B.W. Murdoch Ltd, Broadening Process Engineering and Project Management Capabilities in New Zealand and the Asia Pacific Region 2FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD 2FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD 3FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD 4Reagent Agent(SM) Transfection Cell Line Database From The Transfection Experts 2
(Date:9/22/2014)... have shown that after a long stay in the ... microbe species remain behind in patients, intestines. The team ... become deadly when provoked by conditions that mimic the ... in mBio , the online open-access journal of ... monitoring and treatment of ICU patients who can develop ...
(Date:9/22/2014)... ATLANTA September 23, 2014 A new American ... Supplemental Nutrition Assistance Program (SNAP), previously known as ... scores compared with income eligible non-participants. The authors ... programs aimed at enhancing the dietary quality of ... assist low-income individuals and households with the resources ...
(Date:9/22/2014)... species have vanished from tropical islands because of ... discovered how fossils can be used to restore ... organic materials found in fossil bones, which contain ... a new study available online and in the ... . Pre-human island ecosystems provide vital clues for ...
Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Federal food program puts food on the table, but dietary quality could be improved 2Answer to restoring lost island biodiversity found in fossils 2
... edible crops for biofuels poses a dilemma: Is it ... of an already malnourished population? David Pimentel and his ... problems linked to converting a variety of crops into ... are also economically and environmentally costly and nowhere near ...
... 28, 2009 Mice with increased levels of a natural ... researchers at UT Southwestern Medical Center have found. ... the "weight-loss hormone," leptin, the researchers report. Finding ... as a therapy against obesity, said Dr. Masashi Yanagisawa, professor ...
... 27, 2009 Scientists and engineers will face a ... clean water to millions of people caught up in ... engineers said today at a briefing at the Broadcast ... Report on the American Chemical Society,s Global Challenges/Chemistry Solutions. ...
Cached Biology News:Biofuels ignite food crisis debate 2Natural brain substance blocks weight gain in mice, UT Southwestern researchers discover 2Substantial work ahead for water issues, say scientists at ACS' Final Report briefing 2Substantial work ahead for water issues, say scientists at ACS' Final Report briefing 3
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
CD45/CD34 combination 50 tests...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
XPC Immunogen: XPC (NP_004619, 141 a.a. ~ 251 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: